



ISSN: 0976-3031

Available Online at <http://www.recentscientific.com>

CODEN: IJRSFP (USA)

International Journal of Recent Scientific Research  
Vol. 8, Issue, 9, pp. 19832-19836, September, 2017

**International Journal of  
Recent Scientific  
Research**

DOI: 10.24327/IJRSR

## Research Article

### REMIFENTANIL ATTENUATES SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS UNDERGOING CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS

Hyun Jung Lee<sup>1</sup>, Tran Duc Tin<sup>2</sup>, Jin Young Kim<sup>1</sup>, Hong Bum Bae<sup>1</sup>, Jeong Min Kim<sup>1</sup>,  
Sung Su Chung<sup>1</sup> and Sang Hyun Kwak<sup>1\*</sup>

<sup>1</sup>Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School & Hospital, Gwangju South Korea

<sup>2</sup>Brain Korea 21 Project, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju 501-757, South Korea

DOI: <http://dx.doi.org/10.24327/ijrsr.2017.0809.0769>

#### ARTICLE INFO

##### Article History:

Received 05<sup>th</sup> June, 2017  
Received in revised form 21<sup>st</sup>  
July, 2017  
Accepted 06<sup>th</sup> August, 2017  
Published online 28<sup>th</sup> September, 2017

##### Key Words:

Remifentanil, Cardiac surgery,  
Cytokines, Cardiopulmonary Bypass

#### ABSTRACT

**Background:** Systemic inflammatory response plays pivotal roles in the pathogenesis of organ dysfunction after cardiac surgery with cardiopulmonary bypass (CPB). The aim of this study was to investigate whether remifentanil has the effects on the systemic inflammatory response induced by cardiac surgery with CPB.

**Methods:** Sixty adult patients undergoing cardiac surgery with CPB were randomly assigned to two groups: a remifentanil (n = 30) and a fentanyl group (n = 30). The plasma levels of IL-6, IL-8 and malondialdehyde (MDA) were measured at preinduction (T1), just before aortic clamping (T2), just before aortic declamping (T3), 5 (T4), 30 (T5), and 60 (T6) min after aortic declamping. Hemodynamic variables serially recorded at that same times. Myocardial cell damage as assessed by plasma level of creatine kinase-MB (CK-MB) and troponin T were measured before and 24 hr after surgery.

**Results:** The levels of IL-6, IL-8 and MDA significantly increased from just before aortic declamping in both groups. In the remifentanil group, all of those were significantly lower compared to the fentanyl group from just before aortic declamping (P < 0.05). The level of CK-MB and troponin T significantly increased at 24 hr after surgery than preoperative baseline in both groups. In the remifentanil group, both were significantly lower than fentanyl group at 24 hr after surgery.

**Conclusion:** Remifentanil attenuates systemic inflammatory response more effectively than fentanyl in cardiac surgery with CPB. The mechanism of its effects is likely to be through proinflammatory cytokines (including IL-6, IL-8) and oxidative stress mediator (MDA).

Copyright © Hyun Jung Lee et al, 2017, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

#### INTRODUCTION

The obligatory systemic inflammatory response to cardiac surgery with cardiopulmonary bypass (CPB) has been associated with significant perioperative and long-term morbidity and mortality. Cardiac surgery with CPB initiates a profound systemic inflammatory response, characterized by increased level of inflammatory mediators and oxidative stress mediators which have been shown to be correlated with the incidence of organ dysfunction and adverse clinical outcome.<sup>1</sup>

The pro-inflammatory mediators such as tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6 and IL-8 are associated with anti-inflammatory mediators such as IL-10 and TGF- $\beta$ .<sup>2</sup> However,

the net effect of these circulating inflammatory mediators seems to be distorted as inhibition of innate immune cells, the molecular and cellular mechanisms responsible for suppression of the immune system after cardiac surgery with CPB.<sup>3</sup> In addition, generation of reactive oxygen species (ROS) such as hydrogen peroxide, superoxide and malondialdehyde occurs upon reperfusion following CPB and these may be important contributors to tissue injury.<sup>4</sup> Furthermore, post-CPB coronary endothelial dysfunction appears to be partially mediated by ROS.<sup>5</sup> Opioids have been widely used as anesthetic agents for various types of surgery including cardiac surgery. Several studies found opioid preconditioning had a protective effect on the postischemic heart.<sup>(6-8)</sup> Also, exogenous activation of  $\mu$ -opioid receptor has been shown to ameliorate inflammation in

\*Corresponding author: Sang Hyun Kwak

Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School & Hospital, Gwangju South Korea

experimental colitis,<sup>9</sup> supporting the concept that  $\mu$ -opioid receptor agonists might act as regulatory modulators of gut inflammatory processes. However, no study has examined the direct role of opioids in the expression of pro-inflammatory mediators (including IL-6, and IL-8) and malondialdehyde (MDA) in cardiac surgery with CPB.

These observations provided the background for our hypothesis that exogenous opioids might attenuate the inflammatory response induced by cardiac surgery with CPB. To test our hypothesis, we used fentanyl and remifentanyl as anesthetic agents for cardiac surgery with CPB. The aim of our study was to investigate the effect of exogenous administration of opioids on the systemic inflammatory response induced by cardiac surgery with CPB. We assessed the changes of pro-inflammatory mediators including IL-6, and IL-8, oxidative stress mediator (MDA) and myocardial damage markers such as cardiac troponin T and creatine kinase MB in the patients undergoing cardiac surgery with CPB.

## MATERIALS AND METHODS

### *Patients and study protocol*

The study was approved by Chonnam National University Hospital's Institutional Review Board and written informed consent was obtained. This prospective, randomized study was performed on 60 patients undergoing elective valve replacement using CPB. Patients with ASA classification more than 4, coronary disease requiring surgical revascularization, unstable cardiac function with the need for medical or mechanical inotropic supports, severe hepatic or renal disease, malignancy, preexisting lung parenchymal disease and acute inflammatory response were excluded.

Patients were randomly divided into either the fentanyl group ( $n = 30$ ) who received fentanyl for anesthetic induction ( $3\text{--}10 \mu\text{g/kg}$ ) and maintenance ( $0.03\text{--}0.1 \mu\text{g/kg/min}$ ), and the remifentanyl group ( $n = 30$ ) who received remifentanyl for anesthetic induction ( $0.5\text{--}1.0 \mu\text{g/kg}$ ) and maintenance ( $0.05\text{--}0.1 \mu\text{g/kg/min}$ ).

Preanesthetic medication included midazolam ( $0.1 \text{ mg/kg}$ , PO) and famotidine ( $0.3 \text{ mg/kg}$ , IV). Anesthesia was induced with midazolam ( $0.05\text{--}0.15 \text{ mg/kg}$ , IV), fentanyl or remifentanyl and tracheal intubation was facilitated with rocuronium ( $0.8 \text{ mg/kg}$ ). Patients were mechanically ventilated with 50% oxygen with air to maintain normocarbic ( $\text{PaCO}_2 35 \pm 5 \text{ mmHg}$ ). Anesthesia was maintained with sevoflurane ( $0.5\text{--}1 \text{ vol\%}$ ), and fentanyl or remifentanyl.

The cardiac surgeon and anesthesiologists were blinded to group assignment. CPB was established using a two-stage venous drainage and ascending aortic return. After administration of heparin ( $300 \text{ IU/kg}$ ), standard CPB was started with the priming volume. Body temperature was maintained under mild hypothermia ( $32\text{--}33^\circ\text{C}$ ) with cold blood cardioplegic solution. Pump flow rate was maintained at  $2.0\text{--}2.5 \text{ L/min/m}^2$  of body surface area with mean arterial blood pressure of  $50\text{--}80 \text{ mmHg}$  using non-pulsatile flow.

All patients underwent continuous monitoring with radial artery and pulmonary artery catheters about hemodynamic variables such as mean arterial blood pressure, heart rate, mean

pulmonary artery pressure, central venous pressure, pulmonary capillary wedge pressure, systemic vascular resistance and cardiac index were measured continuously.

Blood was sampled from the radial artery at the following points: preinduction (T1), just before aortic clamping (T2), just before aortic declamping (T3), 5 (T4), 30 (T5), and 60 (T6) min after aortic declamping.

Myocardial cell damage as assessed by plasma level of troponin T and creatine kinase-MB (CK-MB) were measured before and 24 hr after surgery.

### *Determination of cytokines*

Sampled blood was centrifuged at  $3000g$  for 10 min, and the serum was separated and stored at  $-80^\circ\text{C}$  until assayed. In each sample, immunoreactive IL-6, and IL-8 were quantified using commercially available enzyme-linked immunoabsorbant assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer's instructions and as described previously.<sup>10</sup>

### *Determination of malondialdehyde (MDA)*

Serum MDA levels, referred to as thiobarbituric acid-reactive substance (TBARS), were measured according to the method described previously.<sup>11</sup> A volume sample of  $250 \mu\text{l}$  of plasma was added to  $35 \mu\text{l}$  of D/W and the color reaction was initiated by the addition of  $25 \mu\text{l}$  of sodium dodecyl sulfate (SDS) ( $8.1\%$ , W/V) and  $190 \mu\text{l}$  of acetic acid ( $20\%$ ) in thiobarbituric acid ( $0.8\%$ , W/V). The mixture was heated in a boiling water bath for 40 min, until adducts were formed. After the samples were cooled, the TBARS (pink complex color) were extracted with  $0.6 \text{ ml}$  of *n*-butanol:Prydine ( $15:1$ ). Butanol phase was separated by centrifugation at  $12000 \text{ rpm}$  for 10 min. Aliquots of the *n*-butanol phase were placed in a 96 well plate and read at  $532 \text{ nm}$  in a microplate spectrophotometer reader.

### *Determination of troponin T and creatine kinase with muscle and brain subunits (CK-MB)*

Serum troponin T concentration was determined by the Enzyme Immunoassay Method (Enzyme UN-Test Troponin T; Roche Diagnostics, Tokyo, Japan). Normal values were  $< 0.25 \text{ ng/mL}$ . The limit of detection was  $0.11 \text{ ng/mL}$ . Serum isoenzyme of CK-MB concentration was determined by the ultraviolet absorption spectrophotometry method (Merck auto CK-MB; Kanto Chemical, Tokyo, Japan). Normal values were  $< 25 \text{ IU/L}$ . The limit of detection was  $0 \text{ IU/L}$ .

### *Statistical analysis*

Sample size was calculated using cardiac troponin levels at 24 hr after surgery as the primary outcome. A minimum difference of  $0.5 \text{ ng/mL}$  between groups was considered clinically significant. Based on the institutional result for patients who underwent cardiac surgery, the standard deviation of troponin level was  $0.5$ . A sample size of at least 27 in each group was required to achieve a power 0.95 and a 2-side error of 0.05. Considering the 10 % of drop-out rate, 30 patients in each group were enrolled.

All statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA). Data were presented as the number of

patients or the mean±SD. Normal distribution of the data was determined by Shapiro-Wilk test. Demographic and surgical data were analyzed by Mann-Whitney test. Change of cytokines, MDA, cardiac enzymes and hemodynamic variables at different time points were evaluated using repeated measure ANOVA with Tukey post hoc test for normally distributed variables and Friedman test with Duncan post hoc test for non normally distributed variables.  $P < 0.05$  was considered statistically significant.

**RESULTS**

Demographic and surgical data were not different between the two groups (Table 1).

|                             | Fentanyl (n = 30) |   |      | Remifentanyl (n = 30) |   |      |
|-----------------------------|-------------------|---|------|-----------------------|---|------|
| Sex (M/F)                   | 14                | / | 16   | 15                    | / | 15   |
| Age (yr)                    | 55                | ± | 12   | 57                    | ± | 11   |
| Body weight (kg)            | 64.4              | ± | 10.7 | 60.1                  | ± | 12.1 |
| Height (cm)                 | 163.5             | ± | 8.7  | 168.1                 | ± | 7.1  |
| Diabetes mellitus (n)       | 5                 |   |      | 7                     |   |      |
| Hypertension (n)            | 11                |   |      | 12                    |   |      |
| Operation                   |                   |   |      |                       |   |      |
| MVR                         | 16                |   |      | 12                    |   |      |
| AVR                         | 11                |   |      | 14                    |   |      |
| DVR                         | 3                 |   |      | 2                     |   |      |
| Pre-operative LVEF (%)      | 57.8              | ± | 11.3 | 62.4                  | ± | 8.2  |
| Medications                 |                   |   |      |                       |   |      |
| ACE inhibitors (n)          | 10                |   |      | 11                    |   |      |
| Beta blocker (n)            | 5                 |   |      | 5                     |   |      |
| Calcium channel blocker (n) | 11                |   |      | 12                    |   |      |
| Diuretics (n)               | 17                |   |      | 18                    |   |      |
| Statins (n)                 | 13                |   |      | 15                    |   |      |
| Duration of CPB (min)       | 122               | ± | 28.2 | 112                   | ± | 36.5 |
| Duration ACC (min)          | 84                | ± | 44.8 | 74                    | ± | 41.7 |

Values are means ± SD or absolute numbers. MVR: mitral valve replacement, AVR: aortic valve replacement, DVR: double valve replacement, BW: body weight, LVEF: left ventricular ejection fraction, CPB: cardiopulmonary bypass, ACC: aortic cross clamp.

The hemodynamic variables such as MAP, HR, CI, PCWP and SVRI were similar in two groups during the study period (Table 2). The required amount of inotropics, vasopressors and the number of units of blood products transfused per transfused patients were not statistically different between groups (not shown).

The pattern of change in the serum IL-6, IL-8 and MDA level within both groups was similar in the point of significant increase just before aortic declamping compared with preinduction ( $P < 0.001$ ). There were significant differences between both groups just before aortic declamping: In the remifentanyl group, the serum IL-6, IL-8 and MDA level were measured at significantly lower levels compared with the fentanyl group ( $P < 0.05$ ; Table 3). The serum Troponin T and CK-MB levels within both groups were significantly higher at the 24 hr after surgery compared with the preoperative baseline level ( $P < 0.001$ ), and were significantly lower in the remifentanyl group than fentanyl group ( $P < 0.05$ ; Table 4).

**DISCUSSION**

This study evaluated the effects of remifentanyl and fentanyl anesthesia on pro-inflammatory cytokines, oxidative stress mediator and myocardial damage markers induced by cardiac surgery using CPB.

**Table 2 Hemodynamic Data**

|                                                   |   | T1          | T2          | T3         | T4           | T5           | T6           |
|---------------------------------------------------|---|-------------|-------------|------------|--------------|--------------|--------------|
| MAP (mmHg)                                        | F | 86.2 ± 16.6 | 69.7 ± 9.2  | 69.7 ± 7.3 | 75.9 ± 16.5  | 67.7 ± 6.8   | 62.8 ± 4.3   |
|                                                   | R | 93.4 ± 13.3 | 77.7 ± 15.6 | 62.5 ± 8.3 | 65.3 ± 12.7  | 75.3 ± 11.4  | 73.9 ± 17.5  |
| HR (beats/min)                                    | F | 84.5 ± 21.3 | 78 ± 15.5   | -          | 104.8 ± 34.7 | 101.3 ± 20.2 | 107.6 ± 12.4 |
|                                                   | R | 81.8 ± 16.3 | 83.6 ± 16.8 | -          | 111.3 ± 33.8 | 106.9 ± 25.1 | 108.3 ± 21.8 |
| CI (L/m <sup>2</sup> /min)                        | F | 3.2 ± 0.9   | 3.1 ± 0.8   | -          | 2.9 ± 0.7    | 3.0 ± 0.9    | 2.9 ± 0.7    |
|                                                   | R | 3.1 ± 0.8   | 3.3 ± 0.9   | -          | 3.2 ± 0.8    | 3.1 ± 0.8    | 3.0 ± 0.6    |
| PCWP (mmHg)                                       | F | 24.1 ± 9.9  | 23.7 ± 1.8  | -          | 22.9 ± 2.2   | 20.0 ± 2.1   | 22.5 ± 2.2   |
|                                                   | R | 23.3 ± 3.1  | 25.5 ± 3.5  | -          | 25.0 ± 4.4   | 22.2 ± 3.1   | 19.3 ± 2.1   |
| SVRI (dynes.sec/cm <sup>5</sup> /m <sup>2</sup> ) | F | 2980 ± 546  | 2664 ± 401  | -          | 2484 ± 372   | 2571 ± 394   | 2762 ± 443   |
|                                                   | R | 2957 ± 356  | 2872 ± 338  | -          | 2379 ± 315   | 2487 ± 414   | 2581 ± 455   |

Values represent means ±SD. F: fentanyl group (n=30), R: remifentanyl group (n=30), MAP: mean arterial pressure, HR: heart rate, CI: cardiac index, PCWP: pulmonary capillary wedge pressure, SVRI: systemic vascular resistance index. T1: preinduction, T2: just before aortic clamping, T3: just before aortic declamping, T4: 5 min after aortic declamping, T5: 30 min after aortic declamping, T6: 60 min after aortic clamping. \*:  $p < 0.05$  versus T1 values, † $p < 0.05$  versus Fentanyl.

**Table 3 The change of serum cytokine and MDA**

|               |   | T1        | T2        | T3            | T4            | T5             | T6             |
|---------------|---|-----------|-----------|---------------|---------------|----------------|----------------|
| IL-6 (pg/ml)  | F | 1.2 ± 0.6 | 6.8 ± 1.7 | 120.9 ± 20.1* | 179.3 ± 22.1* | 234.4 ± 30.6*  | 255.9 ± 31.0*  |
|               | R | 0.7 ± 0.2 | 4.9 ± 0.7 | 14.7 ± 2.5*†  | 98.6 ± 15.3*† | 158.4 ± 17.8*† | 162.3 ± 17.7*† |
| IL-8 (pg/ml)  | F | 0.8 ± 0.1 | 4.9 ± 1.7 | 42.7 ± 10.9*  | 54.5 ± 10.0*  | 66.2 ± 10.5*   | 113.4 ± 17.3*  |
|               | R | 0.7 ± 0.4 | 1.6 ± 0.5 | 7.5 ± 2.2*†   | 21.8 ± 4.9*†  | 37.7 ± 4.5*†   | 56.0 ± 10.8*†  |
| MDA (nmol/mg) | F | 1.2 ± 0.4 | 1.8 ± 0.5 | 2.5 ± 0.7*    | 2.6 ± 0.4*    | 2.6 ± 0.8*     | 2.7 ± 1.0*     |
|               | R | 1.2 ± 0.2 | 1.8 ± 0.8 | 2.0 ± 0.3*†   | 2.2 ± 0.2*†   | 2.2 ± 0.3*†    | 2.0 ± 0.3*†    |

Values are means ± SD. F: fentanyl group (n=30), R: remifentanyl group (n=30), IL: interleukin, MDA: malondialdehyde. T1: preinduction, T2: just before aortic clamping, T3: just before aortic declamping, T4: 5 min after aortic declamping, T5: 30 min after aortic declamping, T6: 60 min after aortic declamping. \*:  $p < 0.05$  versus T1 values, † $p < 0.05$  versus Fentanyl.

**Table 4** The change of serum Troponin T and CK-MB

|                    | Fentanyl (n = 30) |    | Remifentanyl (n = 30) |               |
|--------------------|-------------------|----|-----------------------|---------------|
| Troponin T (ng/ml) |                   |    |                       |               |
| Pre-OP.            | 0.05              | ±  | 0.00                  | 0.05 ± 0.00   |
| Post-OP.           | 1.01              | ±± | 0.97*                 | 0.40 ± 0.31*† |
| CK-MB (U/L)        |                   |    |                       |               |
| Pre-OP.            | 9                 | ±± | 1.3                   | 8 ± 1.5       |
| Post-OP.           | 50                | ±± | 1.6*                  | 37 ± 13.7*†   |

Values are means ± SD. CK-MB: creatine kinase with muscle and brain subunits.  
\*: p < 0.05 versus Pre-Op. †: p < 0.05 versus Fentanyl.

The remifentanyl ameliorated IL-6, IL-8, MDA, troponin T and CK-MB more than provided by fentanyl. Our study showed that the levels of cytokines and oxidative stress mediator such as MDA during CPB and after aortic declamping (reperfusion) were significantly higher than those preinduction. The heart is inevitably faced with ischemia/reperfusion injury during CPB and after aortic declamping. In addition, inflammatory reaction occurs as a result of neutrophil accumulation in the myocardium. The neutrophils that migrate to the tissue as a result of the inflammatory process initiate the tissue damage by triggering several reactions.<sup>12</sup> Neutrophils that accumulate in the tissue secrete myeloperoxidase, which produces hydroxylchloride (HOCl). HOCl has a direct cytotoxic effect and by inactivating a 1-protease inhibitor, it participates in the production of collagenases and elastases from the neutrophils.<sup>13,14</sup> The neutrophils in this environment favor the secretion of proinflammatory cytokines such as IL-6, IL-8, and TNF- $\alpha$ .<sup>14</sup>

Cytokines are intracellular signaling molecules and elicit important defense mechanisms. However, when the heart was exposed to inflammation and I/R injury during cardiac surgery, cytokines that enhance neutrophil accumulation in the critical organs are excessively produced, and tissues are damaged when elastase and oxygen free radicals are released from neutrophils. Consequently, oxygen free radicals and various cytokines are produced, thus exacerbating microcirculation and tissue damage.<sup>15,16</sup> Excessive inflammatory cytokine production activates neutrophils and enhances the expression of adhesion molecules to exacerbate microcirculation and tissue damage.<sup>17</sup> Therefore, it is important to remove excess amounts of cytokines and active oxygen radicals. In the present study, remifentanyl inhibited the increase of IL-6, IL-8 and MDA after aortic declamping more than those of fentanyl. Although fentanyl has been previously reported to suppress oxygen free radicals and modulate proinflammatory cytokines,<sup>18</sup> the present study is clinically significant because it is the first to clarify the anticytokine and antioxidant activity of remifentanyl in a clinical situation. The results may be attributed that remifentanyl may be potentially useful therapeutic adjuncts more than fentanyl regard to antiinflammatory response and free radical scavengers and believed to be an ideal anesthetic that can be used safely.

Opioids have been widely used as anesthetic agents for various types of surgery, including cardiac surgery. The primary actions of opioids are analgesia and sedation. In addition to their analgesic and sedative effects, opioids modulate the immune response via opioid receptors expressed directly on the immune cells themselves. Recently, it has been suggested that the kappa opioid receptor system has a modulatory role in various

inflammatory diseases. The finding that opioid receptors are expressed in numerous types of immune cells<sup>19-20</sup> gave the first indication that opioids may have a direct effect on the immune system. Also, both endogenous and exogenous opioids alter antibody response, cell-mediated immunity, phagocytic activity, chemotaxis, and respiratory burst responses of neutrophils and mononuclear phagocytes.<sup>21-22</sup> Opioid-induced cardioprotection and ischemic preconditioning (IPC) seem to share a common pathway including protein kinase C and mitochondrial adenosine triphosphate-sensitive potassium (KATP) channels.<sup>23-25</sup> Remifentanyl, an ultrashort-acting opioid, has been shown to trigger both immediate and delayed cardiac preconditioning in the rat heart.<sup>26</sup> Our study demonstrated that remifentanyl has more effective action than fentanyl on the decrease of cytokines and oxidative stress in the cardiac surgery with CPB. The dosages of both drugs, fentanyl and remifentanyl were used on the basis of clinical cardiac anesthesia.<sup>27</sup>

The elevation of cardiac biomarkers such as CK-MB and cardiac troponin T after cardiac surgery has been shown to be a good predictor of clinical outcomes. Most patients undergoing cardiac procedures have some degree of postprocedural cardiac biomarker elevation, however, only significant elevations greater than the normal range (i.e., 10-fold) have been associated with poor outcomes.<sup>28</sup> In this study, both remifentanyl and fentanyl attenuated the elevation of troponin T and CK-MB after cardiac surgery and the levels of postoperative cardiac enzymes in the remifentanyl group were kept significantly lower compared with the fentanyl group. Similarly, Winterhalter et al reported there was a trend towards lower CK-MB level in the remifentanyl group and statistically lower CK-MB and a trend towards lower troponin T level.<sup>29</sup> There are several limitations to this study. First, it was not possible to investigate control group which did not use opioid because the use of opioid is standard anesthesia in cardiac surgery. Therefore, only fentanyl and remifentanyl groups were compared. Second, clinically, postoperative outcomes such as mortality, length of intensive care unit and postoperative complications were not investigated. This study was not primarily designed to assess these parameters. The intraoperative laboratory examination and hemodynamic data only were measured. It is imaginable that the benefit of laboratory data as the meaning of lower myocardial damage will be translated into better clinical outcome. Therefore, it will be important to investigate clinical possibility. Third, in the design of the experimental protocols, TNF- $\alpha$  was designed to be measured at the same time when cytokines were measured. But TNF- $\alpha$  was not found overall in some unexplained reasons. In conclusion, in addition to its analgesic and sedative effects, remifentanyl attenuated inflammatory cytokine (IL-6, and IL-8), oxidative stress mediator (MDA) and myocardial damage markers (Troponin T and CK-MB) and appears to be a promising and useful anesthetic agent for cardioprotection during cardiac surgery with CPB.

## References

1. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisanse DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with

- preserved left ventricular function. *Ann ThoracSurg* 2001; 71: 1428-32.
2. Franke A, Lante W, Fackeldey V, Becker HP, Thode C, Kuhlmann WD, Markewitz A. Proinflammatory and antiinflammatory cytokines after cardiac operation: Different cellular sources at different times. *Ann ThoracSurg* 2002; 74: 363-70.
  3. Wilhelm W, Grundmann U, Rensing H, Werth M, Langemeyer J, Stracke C, Dhingra D, Bauer M. Monocyte deactivation in severe human sepsis or following cardiopulmonary bypass. *Shock* 1992; 17: 354-360.
  4. Barta E, Pechan I, Cornak V, Luknarova O, Rendekova V, Verchovodko P. Protective effect of alpha-tocopherol and L-ascorbic acid against the ischemic-reperfusion injury in patients during open-heart surgery. *BratisLekListy* 1991; 92: 174-83.
  5. Sellke FW, Shafique T, Ely DL, Weintraub RM. Coronary endothelial injury after cardiopulmonary bypass and ischemic cardioplegia is mediated by oxygen-derived free radicals. *Circulation* 1993; 88: 395-400.
  6. Kato R, Foex P. Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kinase C in rats. *Br J Anaesth* 2000; 84: 608-14.
  7. Kato R, Ross S, Foex P. Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A1 receptors and KATP channel linked mechanisms in rats. *Br J Anaesth* 2000; 84: 204-14.
  8. Zhang Y, Irwin MG, Wong TM. Remifentanyl preconditioning protects against ischemic injury in the intact rat heart. *Anesthesiology* 2004; 101: 918-23.
  9. Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P. Antiinflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. *J Clin Invest*. 2003; 111:1329-1338.
  10. Yum HK, Arcaroli J, Kupfner J, Shenkar R, Penninger JM, Sasaki T, Yang KY, Park JS, Abraham E. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. *J Immunol* 2001; 167: 6601-8.
  11. Kikugawa K, Kojima T, Yamaki S, Kosugi H. Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylenediaminetetraacetic acid. *Anal Biochem* 1992; 202: 249-55.
  12. Hayashi Y, Sawa Y, Nishimura M, Tojo SJ, Ichikawa H, Satoh H, Yamaguchi T, Suhara H, Ohtake S, Matsuda H. P-selectin monoclonal antibody may attenuate the whole body inflammatory response induced by cardiopulmonary bypass. *Asaio J* 2000; 46: 334-7.
  13. Ossanna PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interactions. *J Clin Invest* 1986; 77: 1939-51.
  14. Sullivan GW, Carper HT, Novick WJ, Jr., Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. *Infect Immun* 1988; 56: 1722-9.
  15. Kraemer R, Seligmann B, Mullane KM. Polymorphonuclear leukocytes reduce cardiac function in vitro by release of H<sub>2</sub>O<sub>2</sub>. *Am J Physiol* 1990; 258: H1847-55.
  16. Suematsu M, DeLano FA, Poole D, Engler RL, Miyasaka M, Zweifach BW, Schmid-Schonbein GW. Spatial and temporal correlation between leukocyte behavior and cell injury in postischemic rat skeletal muscle microcirculation. *Lab Invest* 1994; 70: 684-95.
  17. Paccaud JP, Schifferli JA, Baggolini M. NAP-1/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes. *BiochemBiophys Res Commun* 1990; 166: 187-92.
  18. Raut A, Ratka A. Oxidative damage and sensitivity to nociceptive stimulus and opioids in aging rats. *Neurobiol Aging* 2009;30:910-9.
  19. Doerschuk CM, Tasaka S, Wang Q. CD11/CD18-dependent and -independent neutrophil emigration in the lungs: how do neutrophils know which route to take? *Am J Respir Cell MolBiol* 2000; 23: 133-6.
  20. Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide oxidase. *J Immunol* 1997; 159: 5070-8.
  21. Parkhill AL, Bidlack JM. Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50, 488 in a mouse monocyte-like cell line. *IntImmunopharmacol* 2006; 6: 1013-9.
  22. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. *Trends Immunol* 2003; 24: 116-21.
  23. Gross GJ. Role of opioids in acute and delayed preconditioning. *J Mol Cell Cardiol* 2003; 35: 709-18.
  24. Schultz JE, Gross GJ. Opioids and cardioprotection. *PharmacolTher* 2001; 89: 123-37.
  25. Zhang Y, Chen ZW, Girwin M, Wong TM. Remifentanyl mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. *ActaPharmacol Sin* 2005; 26: 546-50.
  26. Yu CK, Li YH, Wong GT, Wong TM, Irwin MG. Remifentanyl preconditioning confers delayed cardioprotection in the rat. *Br J Anaesth*. 2007 ;99:632-8.
  27. Mehta AR, Romanoff ME, Licina MG. Anesthetic Management in the Precardiopulmonary Bypass Period. In: Hensley FA, ed. *A Practical Approach to Cardiac Anesthesia*. fifth Edition. Philadelphia: Lippincott Williams & Wilkins 2013: 179-191.
  28. Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC. Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. *Catheter CardiovascInterv*. 2011; 77:020-30.
  29. Winterhalter M, Brandl K, Rahe-Meyer N, Osthaus A, Hecker H, Hagl C, Adams HA, Piepenbrock S. Endocrine stress response and inflammatory activation during CABG surgery. A randomized trial comparing remifentanyl infusion to intermittent fentanyl. *Eur J Anaesthesiol*. 2008;25:326-35.